GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future

被引:2
|
作者
Trott, Mike [1 ,2 ,3 ]
Arnautovska, Urska [1 ,2 ,3 ]
Siskind, Dan [1 ,2 ,3 ]
机构
[1] Univ Queensland, Fac Med, Brisbane, Australia
[2] Queensland Ctr Mental Hlth Res, Wacol, Australia
[3] Metro South Addict & Mental Hlth Serv, Brisbane, Qld, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
antipsychotic; glucagon-like peptide-1; psychosis; weight loss; OBESITY; OVERWEIGHT; ADULTS; MG;
D O I
10.1097/YCO.0000000000000952
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of reviewPeople with schizophrenia experience three to five times higher prevalence of diabetes and obesity than the general population, contributing to a 20-year reduced lifespan. The impacts of weight gain extend beyond physical health, affecting people's self-esteem, quality of life, and triggering treatment nonadherence, leading to relapse and deteriorations in health. Clinical guidelines recommend patients with antipsychotic-induced weight gain are treated with cognitive behaviour therapy and lifestyle changes; however, effective treatments for obesity in schizophrenia are critically lacking. Glucagon-like peptide-1 receptor agonists (GLP-RAs) have shown large effects in weight loss in the general population; however, effects are less clear in people with schizophrenia. This review aims to assess the clinical trials that have been completed, are in progress, and directions for future trials.Recent findingsTo date, six clinical trials have been completed, four of which have published their findings. Three further trials are currently in progress.SummaryResults from completed trials suggest that GLP-1RAs decrease weight in people with schizophrenia, however effect sizes are mostly smaller than studies based on the general population. Future trials could focus on dual or triple agonist agents, and/or explore the effects of GLP-1 s at antipsychotic medication commencement, to potentially prevent antipsychotic weight gain.
引用
收藏
页码:363 / 369
页数:7
相关论文
共 50 条
  • [21] GLP-1 Receptor Agonists in Weight Loss and Bariatric Surgery: Balancing Efficacy and Gastrointestinal Adverse Events
    Au, Kahei
    Yang, Wah
    OBESITY SURGERY, 2024, 34 (02) : 429 - 441
  • [22] The extent and predictors of off-label use of GLP-1 receptor agonists for weight loss management
    Siudak, Zbigniew
    Tkaczyk, Filip
    Tomaszewska, Monika
    Malinowski, Krzysztof P.
    Szarpak, Lukasz
    Kowalska-Bobko, Iwona
    DIABETES OBESITY & METABOLISM, 2025,
  • [23] Advances in GLP-1 receptor agonists for pain treatment and their future potential
    He, Yongtao
    Xu, Biao
    Zhang, Mengna
    Chen, Dan
    Wu, Shuyuan
    Gao, Jie
    Liu, Yongpeng
    Zhang, Zixin
    Kuang, Junzhe
    Fang, Quan
    JOURNAL OF HEADACHE AND PAIN, 2025, 26 (01):
  • [24] GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
    Ilias, Ioannis
    Zabuliene, Lina
    Rizzo, Manfredi
    FRONTIERS IN CLINICAL DIABETES AND HEALTHCARE, 2025, 5
  • [25] The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes
    Dar, Shujah
    Tahrani, Abd A.
    Piya, Milan K.
    PRACTICAL DIABETES, 2015, 32 (08) : 295 - 300
  • [26] Liraglutide, GLP-1 receptor agonist, for chronic weight loss
    Moore, Katherine G.
    Shealy, Kayce
    Clements, Jennifer N.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (05) : 373 - 378
  • [27] An updated patent review of GLP-1 receptor agonists (2020-present)
    Lu, Weiwen
    Zhou, Zhongbo
    Jiang, Neng
    Han, Jing
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2023, 33 (09) : 597 - 612
  • [28] GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 383 : 2330
  • [30] Weight loss mechanisms with GLP-1
    Holst, J. J.
    DIABETES OBESITY & METABOLISM, 2010, 12 : 25 - 25